| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SAP3 |
| Uniprot No | P17900 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 32-193aa |
| 氨基酸序列 | SSFSWDNCDEGKDPAVIRSLTLEPDPIIVPGNVTLSVMGSTSVPLSSPLKVDLVLEKEVAGLWIKIPCTDYIGSCTFEHFCDVLDMLIPTGEPCPEPLRTYGLPCHCPFKEGTYSLPKSEFVVPDLELPSWLTTGNYRIESVLSSSGKRLGCIKIAASLKGI |
| 预测分子量 | 33.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SAP3重组蛋白的3篇参考文献及其摘要内容：
1. **文献名称**：*Role of Secreted Aspartic Protease 3 in Candida albicans Pathogenesis*
**作者**：White, T.C. 等
**摘要**：研究白色念珠菌分泌型天冬氨酸蛋白酶SAP3的毒力作用，通过基因敲除实验表明SAP3在真菌侵袭宿主组织及免疫逃逸中起关键作用，重组SAP3蛋白体外实验证实其降解宿主屏障蛋白的能力。
2. **文献名称**：*Expression and Characterization of Recombinant SAP3 for Serodiagnosis of Candidiasis*
**作者**：Müller, M. 等
**摘要**：报道在大肠杆菌中高效表达重组SAP3蛋白，并验证其抗原性。通过患者血清分析，证明重组SAP3可作为念珠菌病血清学诊断的敏感标记物。
3. **文献名称**：*Structural Insights into SAP3 Protease Activity and Inhibition*
**作者**：Lee, J.E. 等
**摘要**：通过X射线晶体学解析重组SAP3的三维结构，揭示其底物结合位点及催化机制，为开发靶向SAP3的抗真菌药物提供结构基础。
(注：以上文献信息为示例，实际引用时需核对真实文献来源及作者信息。)
SAP3 (Serine Protease 3), also known as kallikrein-related peptidase 7 (KLK7), is a member of the serine protease family with significant roles in skin homeostasis, inflammation, and tissue remodeling. It is primarily expressed in the epidermis, where it contributes to the desquamation process by cleaving corneodesmosomal proteins to facilitate the shedding of dead skin cells. Structurally, SAP3 consists of a catalytic triad (His, Asp, Ser) common to serine proteases and operates optimally at neutral to slightly alkaline pH. Its activity is tightly regulated by endogenous inhibitors like LEKTI (lympho-epithelial Kazal-type inhibitor) to prevent excessive proteolysis, which could lead to barrier dysfunction or inflammatory skin disorders.
Recombinant SAP3 is produced using heterologous expression systems (e.g., Escherichia coli, mammalian cells) for biochemical and therapeutic studies. Purification typically involves affinity chromatography tags and refolding steps to ensure enzymatic activity. Research highlights its involvement in pathological conditions such as atopic dermatitis, psoriasis, and Netherton syndrome, where dysregulated SAP3 activity disrupts epidermal integrity. Additionally, SAP3 overexpression has been implicated in cancer progression, particularly in tumor microenvironment modulation and extracellular matrix degradation.
Recent studies explore SAP3 as a diagnostic biomarker and therapeutic target. Inhibitors, including small molecules and monoclonal antibodies, are under investigation to mitigate its pathological effects. The recombinant protein also serves as a tool to study protease-substrate interactions and develop topical agents for skin diseases. Its dual role in physiological maintenance and disease pathogenesis underscores the importance of SAP3 in both basic research and clinical applications.
×
